X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Oculis intends to use the net proceeds from the Financing to advance and accelerate its clinical development pipeline, OCS-02 (licaminlimab), a novel TNF alpha antibody eye drop, currently being investigated in phase 2 for the treatment of dry eye disease and uveitis.
Lead Product(s): Licaminlimab
Therapeutic Area: Ophthalmology Product Name: OCS-02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Undisclosed
Deal Size: $59.0 million Upfront Cash: Undisclosed
Deal Type: Financing April 11, 2024
Details:
OCS-01 (dexamethasone) is a glucocorticoid receptor agonist, which is being evaluated in phase 3 clinical trials for the treatment of inflammation and pain following cataract surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Neurology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2023
Details:
OCS-01 (dexamethasone) is a novel, high concentration (15 mg/ml), topical formulation of dexamethasone. It is under phase 3 clinical development for the treatment of Diabetic Macular Edema.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2023
Details:
Oculis' investigational product OCS-02 (licaminlimab) is an innovative anti-TNFα biologic eye drop. It is currently undergoing Phase II clinical trial evaluation for treating Dry Eye Disease.
Lead Product(s): Licaminlimab
Therapeutic Area: Ophthalmology Product Name: OCS-02
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 07, 2023
Details:
OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical OPTIREACH® formulation of dexamethasone is being developed for the treatment of inflammation and pain following ocular surgery.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 08, 2023
Details:
OCS-01 is developed using the Optireach® solubilizing technology, a proprietary platform that enables the formulation of drugs as topical eye drop treatment with cystoid macular edema.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 02, 2023
Details:
Oculis will fund its development programs in Diabetic Macular Edema and other ophthalmic indications, including OCS-01's NDA enabling activities. OCS-01 (dexamethasone) eye drops is developed using the Optireach® solubilizing technology for the treatment of DME.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: BofA Securities
Deal Size: $40.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering May 31, 2023
Details:
OCS-01 (dexamethasone) has been developed using the OPTIREACH solubilizing nanoparticle technology, enabing the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 22, 2023
Details:
OCS-01 (dexamethasone) has been developed using the OPTIREACH solubilizing nanoparticle technology, enabing the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2023
Details:
OCS-01 (Dexamethasone) has been developed using the OPTIREACH solubilizing nanoparticle technology, enabing the formulation of drugs as non-invasive topical treatments, a longer residence time on the eye surface and enhances their bioavailability in the relevant eye tissues.
Lead Product(s): Dexamethasone
Therapeutic Area: Ophthalmology Product Name: OCS-01
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 04, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
